A typical obstacle to cancer therapy is the limited distribution of low-molecular weight anticancer drugs within the carcinoma tissue. In experimental carcinoma, Imatinib (STI571) increases efficacy of synchronized chemotherapy, reduces tumor interstitial fluid pressure and increases interstitial fluid volume. STI571 also increases the water-perfusable fraction in metastases from human colorectal adenocarcinomas. Because the mechanism(s) behind these effects have not been fully elucidated, we investigated the hypothesis that STI571 alters specific properties of the stromal extracellular matrix. We analyzed STI571-treated human colorectal KAT-4/HT-29 experimental carcinomas, known to have a well-developed stromal compartment, for solute exchange and glycosaminoglycan content, as well as collagen content, structure and synthesis. Magnetic resonance imaging of STI571-treated KAT-4/HT-
Introduction
Carcinomas are characterized by a deranged vasculature with aberrant blood flow and leaky blood vessels, leucocyte infiltrates and a dense and often a fibrotic stromal extracellular matrix (ECM). In addition, a pathologically elevated interstitial fluid pressure (IFP) characterizes both human and experimental carcinomas. These stromal properties contribute to the limited distribution of blood-borne drugs within carcinoma tissue (1) (2) (3) .
Several agents that lower IFP in experimental carcinomas increase the interstitial fluid volume in parallel to an increase of the uptake and efficacy of small molecular weight chemotherapeutic agents (1, (4) (5) (6) . Previous studies have revealed a correlation between IFP and the properties of the collagen network in stroma such as collagen fibril density, fibril structure or network architecture in experimental carcinomas (7) (8) (9) (10) (11) . In normal loose connective tissues IFP is actively controlled by connective tissue cells that exert a tension on the collagen/microfibrillar network, thereby restraining the swelling of the underhydrated glycosaminoglycan (GAG)/proteoglycan ground substance (12) . Increases in GAG/proteoglycan ground substance will increase IFP provided there is a collagen network that resists the tendency towards increased swelling. Such an example was demonstrated in pancreatic ductal adenocarcinomas (PDAC) where high concentrations of both collagen type I and the GAG hyaluronan correlated with a particularly high IFP and solid stress in the stroma (13) . In a therapeutic experiment, enzymatic degradation of hyaluronan lowered IFP, restored blood flow and improved efficacy of gemcitabine (13) . Another study with an experimental model of PDAC showed that inhibition of the Hedgehog cellular signaling pathway reduced stromal fibrosis, reduced collagen content, increased blood flow and efficacy of gemcitabine (14) . STI571 is a low molecular weight tyrosine kinase inhibitor originally developed for the treatment of chronic myeloid leukemia by blocking the kinase activity of the pathogenic BcrAbl fusion protein (15, 16) . STI571 also selectively inhibits the intrinsic receptor tyrosine kinases in discoidin domain receptors, c-Kit, colony stimulating factor-1 receptor (CSF-1R), and PDGF receptor-α and -β (16, 17) . STI571 lowers tumor IFP in several models of experimental carcinoma (including the KAT-4/HT-29 model) without affecting tumor growth (18). Furthermore, STI571 treatment of the ECM-rich KAT-4/HT-29 carcinoma model increases the extracellular fluid (ECV) volume from 34% to 42% of total tissue water (TTW), without significantly altering plasma volume (about 0.9% of the TTW) (19). TTW is the sum of intracellular, ECV and plasma. Since the ECV is largely contained within the interstitial (stromal) ECM-compartment (12) the data suggest that treatment with STI571 increases the volume of the ECM in the carcinoma and that this compartment amounts to about 25% of the carcinoma volume. These preclinical data agree with the findings that treatment of patients with STI571 increases the water-perfusable tumor fraction in metastases from colorectal adenocarcinoma (20) . In the present study we used magnetic resonance imaging (MRI) to investigate how STI571 affects the uptake of low-molecular weight contrast agents. We also analyzed the stromal ECM to investigate potential ECM-related mechanisms that could influence the solute exchange between blood and tumor tissue.
Materials and methods

Tumor model
KAT-4 (ATCC, Manassas, VA, USA) carcinoma cells were cultured in DMEM or RPMI 1640 (Invitrogen, San Diego, CA, USA) supplemented with 10 % Fetal Bovine Sera (Saveen- 
Treatment of animals
Tumor size was measured externally with a caliper. Tumors that had reached volumes between 0.2 -0.4 mL were randomized into two groups. A treatment group received STI571
(Kindly donated by Novartis, Basel, Switzerland) 100 mg/kg/day dissolved in PBS and a vehicle group received only PBS. In both groups the substances were administered orally via gavage for four consecutive days.
MRI
Animals were anesthetized with 3.5% isoflurane in mixture of 200 mL/min oxygen and 200 mL/min nitrous oxide and maintained at 1.5-2% isoflurane. Inside the magnet, the respiratory rate of the animal was monitored and the body temperature was maintained at 37°C using warm air (SA Instruments Inc, New York, USA). Contrast-enhanced MR imaging was performed with a 9.4 T MR scanner (Agilent Inc, Palo Alto, USA) equipped with a 6 cm inner diameter gradient system having a maximum gradient strength of 1000 mT/m. Reference scans were acquired to ensure the correct animal position inside the magnet and a total of 23 slices were defined with a gap of 0.25 mm to image the whole tumor area. The animal was taken out of the magnet and 100 μL of Omniscan (Gd-DTPA-BMA) (GE Healthcare) was injected intraperitoneally with care taken not to move the position of the animal. With the animal placed back in the magnet, contrast-enhanced MR images were acquired using T1-weighted gradient echo sequence (TR: 100 ms, TE: 2 ms, number of averages: 8, resolution in plane 117 μm x 117 μm, slice thickness 0.5 mm). Total scan time was 3 minutes and scans were started with 10 minutes interval. Animals were scanned until a clear decrease of the contrast enhancement could be observed in the connective tissue. Typically, the animals were scanned 60-80 minutes post-injection. Mice were euthanized after the measurements.
MRI data analysis
Analysis was carried out using in-house written Matlab scripts (MathWorks, Natick, Massachusetts). The first images after injection when no contrast enhancement could be detected were used as reference. The carcinoma tissue was manually delineated on all slices and marked as region of interest (ROI). The tumor volume was calculated by multiplying the total amount of pixels in the ROI in all slices. For all pixels originating from the tumor tissue, the change of signal was plotted as a function of time. To reduce processing time, images were down-sampled with a factor of 2 prior to curve fitting. The data was filtered using principal component analysis (PCA) (24) in which the 2 first components, representing more than 95% of the variation of the data, were used to reconstruct the data. Quantitative model fitting of this kind of data exists (25) but in this study a more qualitative description of the data was chosen. We considered only the pixels with a signal change greater than three standard deviations of the noise in the image after PCA. Thus, around 10% of the total number of pixels was not considered due to lack of any significant signal enhancement. The change in the signal of a pixel inside the tumor was fitted to three model line shapes; a linear enhancement, a mono-exponential enhancement (wash-in) and a bi-exponential enhancement (wash-in / wash-out). The most appropriate curve describing the pixel enhancement was chosen from the best correlation coefficient R 2 calculated after the fit. 
Hydroxyproline determinations.
KAT-4/HT-29 carcinomas were hydrolyzed in 6M HCl for 4 hours at 120°C at a pressure of 2 atmospheres. Hydroxyproline content in the hydrolysates was determined essentially as described (26) .
Disaccharide fingerprint.
KAT-4/HT-29 carcinoma tissues from STI571-treated and control tumors were lyophilized.
GAG preparation, lyase treatment, fluorescence disaccharide labeling and separation were performed according to (27) . Briefly, tumors were protease and DNAase digested, and GAGs were purified on anion-exchange chromatography. GAGs were roughly estimated by the carbazol method. Then, 500ng of GAGs was subjected to chondroitinase ABC (Sigma) degradation or degradation with a mixture of heparinases (in house preparation, purified from with HPLC-fluorescence as described previously (27) . Quantification was done by comparison to known weight of mock-treated standard disaccharides (Iduron, UK).
Electron microscopy (EM).
For transmission EM analysis, KAT-4/HT-29 carcinoma from control and STI571-treated mice were fixed in 0.15 M sodium cacodylate-buffered 2.5 % glutaraldehyde, post-fixed in 0.15 M sodium cacodylate-buffered 1% osmium tetraoxide, dehydrated in graded ethanol series, impregnated in acetone and embedded in epoxy resin. Ultra-thin sections were examined in a Philips CM-10 electron microscope (Philips, Amsterdam, Netherlands) and the micrographs were quantified with ImageJ software (NIH, Bethesda, MD, USA). For scanning EM analysis, KAT-4 tumors from PBS and STI571 treated mice were processed by alkali maceration as described (28) and analyzed in a Philips 515 electron microscope.
Ex vivo collagen synthesis
Tumors were excised and cut into 300-700 µm slices with a vibratome (Bannockburn, IL, USA). Samples were weighed (average wet weight 169±20 mg, of all 18 samples) and kept on 9 37° C in a humidified incubator for 6 hours. Thereafter the samples were dried in a vacuum centrifuge. Collagen was solubilized in 0.5 M HAc containing 3 mg/ml pepsin (Sigma) pH 2.5 for 24 hours at 4° C. The samples were centrifuged 17,000 x g for 30 min at 4° C and supernatants collected. The supernatants were mixed with 2.8 M NaCl in order to obtain a final concentration of 0.7 M NaCl, in which native triple helical collagen was precipitated.
Precipitated collagen was washed two times in 0.5 M HAc containing 0.7 M NaCl. Dry pellets were stored frozen, pending further analysis. Each pellet was solubilized in equal amounts of 2 x sample buffer (0.2 M Tris-HCl pH 8.8 (Sigma), 18% Glycerol (Merck, Darmstadt, Germany), 0.01 % Bromphenol blue (Merck), 4% SDS (Merck), 10% 2-Mercaptoethanol (BDH, Poole, UK)) and heated at 100° C for 10 min. The samples were run on 6 % SDS-PAGE gels after which the gels were stained by Coomassie blue and dried. The dried gels were exposed to an imaging plate (Fuji, Stockholm, Sweden) and developed in BAS-2500 Bioimaging analyzer (Fuji). Band intensities were normalized to the individual wet tissue weight.
RT-PCR and Real-time qPCR
Total RNA was extracted from tumors (five biological replicates) using Trizol reagent (Thermofisher). 500 ng RNA was used for reversed transcription using Superscript VILO (Thermofisher). Real-time qPCR was performed with Taqman probes listed in Supplemental Table, using an Applied Biosystems 7300 detection system. Gene expression was normalized to Actb transcript.
Immunofluorescence.
Tumors were snap-frozen in isopentane at -80° C, embedded in OCT (Sakura, Torrence CA, USA) and sectioned. 
Results
STI571 treatment increased exchange between plasma and interstitial fluid in KAT-4/HT-29 experimental carcinoma
MRI was used to determine wash-in and wash-out characteristics in KAT-4/HT-29 carcinomas. The average volumes of the investigated KAT-4/HT-29 carcinomas as determined by MRI were not different between the STI571-treated (0.14 ± 0.12 mL, n = 9) and the control group (0.15 ± 0.08 mL, n = 8). The distribution of the low-molecular weight MRI contrast agent Omniscan within the extracellular fluid of experimental carcinomas was followed during a 60 -80 min time course per tumor. Omniscan quickly and freely distributes to the extracellular space where its elimination tends to be rapid and complete (29) . The contrast signal confidently represents extracellular fluid as uptake by cultured cells has been shown to be ineffective and requires prolonged incubation times (30) . Dynamic contrastenhanced MRI data was recorded and analyzed for each individual pixel. Contrast enhancement in the pixels followed time courses which fit best either with bi-exponential, mono-exponential or linear enhancement curves as exemplified in Figure 1 . The total number of pixels having significant signal enhancement from all STI571-treated (n = 9) and control (n=8) tumors, respectively, were pooled and compared. Thus a total of ≈33,000 pixels from the STI571-treated group and ≈25,000 from the control group were examined. A majority of the pixels in both groups followed a bi-exponential enhancement curve (Fig. 1A) , around 11-12 % followed a mono-exponential (Fig. 1B) and less than 7.5% followed a linear enhancement curve (Fig. 1C) . In these distributions no significant differences were recorded between the treatment and control group. On the other hand, STI571-treated carcinomas displayed significant increases in time constants in pixels following mono-exponential washin enhancement curves ( Fig. 2A) and bi-exponential wash-in (Fig. 2B ) and wash-out (Fig. 2C) enhancement curves (p<0.001 in Fig. 2A-C) . Furthermore, the pixels best described by monoexponential uptake enhancement curves revealed a significant shift towards higher signal amplitudes (Fig. 2D, p<0 .001), indicating an increased uptake after STI571 treatment. When bi-exponential wash-out time constants per tumor were compared between the groups the STI571-treated tumors displayed a significantly higher average (Fig. 2F, p=0.047 ). Together the data shows that STI571 treatment increased the dynamic exchange of solutes between blood and carcinoma tissue. 
STI571 treatment decreased collagen fibril diameter
Electron microscopy was used to assess the overall structure of the collagen network in STI571-treated and control KAT-4/HT-29 tumors. Transmission EM revealed a difference in collagen fibril diameter and morphology: collagen fibrils in STI571-treated tumors were more heterogeneous in diameter and had distorted surface morphology, whereas fibrils in PBStreated tumors were more uniform and had a smooth surface (Fig. 3A) . Quantification revealed a Gaussian distribution of collagen fibril diameters in control tumors, whereas a skewed distribution towards thinner fibril diameters was apparent in STI571-treated tumors (Fig. 3B) . This was also reflected in the average collagen fibril diameter, which was 35 nm in STI571-treated mice and 45 nm in control carcinoma ( Fig. 3C; p<0 .029). These results show that STI571 alters the collagen fibril thickness and morphology, indicating an effect on cell signaling-regulated collagen fibril assembly.
No effect of STI571 on the amount or structure of GAGs in tumors.
GAGs were extracted and purified from tumors. Chondroitin sulfate (CS)/dermatan sulfate (DS), hyaluronan (HA) or heparan sulfate (HS) fluorescent-labeled disaccharides were obtained after chondroitinase ABC or a mixture of heparinases treatment, respectively, and quantified after HPLC separation. No differences were seen in the amounts of CS/DS, HA, or HS between STI571-treated or control tumors (coefficient of variations ranged from 9 to 19%) (Fig. 4A) . In KAT-4/HT-29 carcinomas the high level of HS, representing 33% of total GAGs, most likely reflects a high number of HS-expressing carcinoma cells (31) . No differences in the structure of the CS/DS or HS chains between STI571-treated or control tumors could be detected (Table I) . 
STI571 treatment did not significantly affect total collagen content.
The observed decrease in fibril diameter in KAT-4/HT-29 tumors from STI571-treated mice could reflect a decreased collagen content. Hydroxyproline measurements indicated a tendency to this effect in STI571-treated tumors; the decrease, however, was not statistically significant (Fig. 4B) . A similar trend but no significant difference in hydroxyproline content was observed in carcinomas grown in animals treated with STI571 for 8 days compared to vehicle-treated tumors (1.13 ± 0.52 mg/g wet weight, n = 4, p > 0.2 versus pooled controls).
STI571-treatment significantly increased collagen type I synthesis but did not affect collagen gene expression
The KAT-4/HT-29 carcinoma is rich in ECM and has a well-developed stromal compartment (8, 19, 32) . Treatment with STI571 had no discernable effect on the gross appearance of the collagenous matrix as judged from stainings with Sirius red (Fig. 5A ). Gene expression of collagens, small leucine-rich proteoglycans, and enzymes involved in post-translational modifications of collagens varied largely in KAT-4/HT-29 carcinomas (Supplementary Table   S1 ). STI571 treatment had no significant effect on expression levels of most transcripts, except for a significantly increased expression of the Lox and Loxl2 genes. Next, we investigated whether STI571-treatment affected collagen synthesis. Metabolic labeling ex vivo for 6 hours of freshly isolated thick sections from STI571-and vehicle-treated carcinomas, revealed a significantly increased de novo synthesis of pepsin-resistant collagen type I in STI571-treated carcinoma ( Figure 4C and Supplementary Fig. S1 ). The amounts of pepsinresistant collagen from the sections did not differ between STI571-and vehicle-treated carcinomas when normalized to tissue wet weights (Supplemental Fig. S1 ). 
STI571 treatment did not affect endothelial staining and pericyte coverage, but reduced an NG2-positive extravascular cell population in the tumor stroma.
Sections from KAT-4/HT-29 carcinomas grown in STI571-treated and control mice were stained for the endothelial marker CD31, smooth muscle actin (α-SMA), Reticular Fibroblast Marker (RFM), macrophages (F4/80) and the pericyte marker NG2 (Fig. 5A) . STI571 treatment had no apparent effect on the number of cells expressing RFM and α-SMA (Fig.   5B ), i.e. cells that could be both mural pericytes (33) and stromal myofibroblasts (34, 35) .
STI571 induced a decreased number of F4/80-positive macrophages (Fig. 5B) ; this reduction, however, was not statistically significant. Total NG2 staining was significantly decreased (p<0.05) by STI571 treatment (Fig. 5A and B) . Quantification of pixels representing blood vessels (CD31) and NG2-positive pericytes showed that the ratio between co-localized CD31 and NG2 versus CD31 alone was unaltered in STI571-treated tumors, i.e. no difference in vascular NG2 positive pericyte-coverage was detected ( Fig. 5A and C) . Thus, it can be are likely to show bi-exponential enhancement in our model, i.e. wash-in and -out dynamics, while the pixels further away from the blood vessels should tend to follow a monoexponential uptake curve, i.e. wash-in flow. The contrast agent may diffuse from one pixel to another over time and a linear uptake is likely due to diffusion to areas with mono-exponential uptake profiles (36) Consequently, in the comparison between the different uptake curves between control and STI571-treated groups, a change in the bi-exponential time constants will directly influence the diffusion into the mono-exponential areas. Despite the faster wash-out of contrast agent in the STI571-treated animals, a faster mono-exponential uptake was evident. This finding strongly indicates that STI71 improves transport of solutes through the stroma interstitium thereby making it more accessible for blood stream solutes. Our present data therefore provide one plausible contributing mechanism for the enhanced efficacy of taxol (18) STI571 had no effect on the density of CD31-positive vessels in KAT-4/HT-29 carcinoma, consistent with our earlier findings (19). Furthermore, our data show that the pericyte coverage of CD31 positive vessels was not affected by STI571 treatment. Although STI571-treatment does not affect plasma volume in KAT-4/HT-29 carcinomas but has been shown to reduce blood vessel perimeters (19) it cannot be excluded that STI571 increases blood flow through the tumor. Available data have indeed shown that modulation of the ECMcomposition, notably the major ECM-constituents collagen and/or glycosaminoglycans, influence solid stress in carcinoma and thereby compression of blood vessels (13, 14, 46) . A less dense and more flexible collagen network would enable the opening of vessels and increase blood flow. It is thus possible that STI571 by altering the collagen ultra-structure has a dual function that increases drug distribution within carcinoma, by improving transport through the stroma and, potentially, tumor blood flow. Together, our data suggest that STI571 (Imatinib/Gleevec) improves the distribution of low molecular weight compounds into carcinoma interstitium by altering the collagen ultrastructure, but not the overall content of collagen or glycosaminoglycans. Drugs that specifically alter collagen ultra-structure should be important tools in improving the uptake, and thereby efficacy, of commonly used chemotherapeutics. Table I .
Compositional analysis of CS/DS and HS chains. Data are expressed as mole % of the disaccharide units (mean ± SDEV of duplicates). 
CS/DS
PBS STI571 ΔUA-GalNAc ( ΔO ) 16.1 ± 1.0 15.7 ± 1.4 ΔUA-GalNAc-4S (ΔA ) 80.2 ± 1.1 80.4 ± 1.4 ΔUA-GalNAc-6S ( ΔC ) 1.8 ± 0.1 1.9 ± 0.2 ΔUA-2S-GalNAc-4S ( ΔB ) 1.9 ± 0.2 2.0 ± 0.2 ΔUA-2S-GalNAc-6S (ΔD) < 0.1 < 0.1 ΔUA-GalNAc-4S,
